Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs The price of cancer drugs has risen, drawing criticism from leading academics.1,2 The annual cost of a new cancer medication now routinely exceeds $100 000, and medical bills have become the single largest cause of personal bankruptcy.2 Although some contend that the high cost of drugs is required to support re-search and development efforts,3 the fact remains that when costs and revenues are balanced, the pharmaceutical industry generates high profit margins.4 High profits may be justified if novel products offer significant benefits to patients (thus producing indirect economic value through the patients’ restored health) or if they represent significant pharmacologic advances over their predecessors—offering new mechanisms of actions and emblematic of high-risk research. We investigated whether novelty of medications or their relative benefits affected drug pricing.
[1]
T. Fojo,et al.
Cancer drugs in the United States: Justum Pretium--the just price.
,
2013,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2]
P. Bach.
Limits on Medicare's ability to control rising spending on cancer drugs.
,
2009,
The New England journal of medicine.
[3]
V. Prasad,et al.
Comparative effectiveness questions in oncology.
,
2014,
The New England journal of medicine.
[4]
Francisco Cervantes,et al.
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.
,
2013,
Blood.